

ISF.405.89.2025.IP.2 WTC/0012\_01\_01/190

## CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER<sup>1</sup>

## Part 1

Issued following an inspection in accordance with Art. 94(1) of Regulation (EU) 2019/6

## **Chief Pharmaceutical Inspector**

/the Competent Authority of Poland/ confirms the following:

the manufacturer

Instytut Chemii i Techniki Jądrowej ul. Dorodna 16, 03-195 Warszawa, POLAND

site address

Instytut Chemii i Techniki Jądrowej ul. Dorodna 16, 03-195 Warszawa, POLAND

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. **014/0012/15** in accordance with Art. 88 of Regulation (EU) 2019/6 Art. 38 and Art. 51a point 2 Pharmaceutical Law of 6th of September 2001 (Journal of Laws from 2025, item 750 as amended).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 03/06/2025 – 05/06/2025, it is considered that it complies with the Good Manufacturing Practice laid down in Directive 91/412/EEC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (<a href="http://eudragmdp.ema.europa.eu">http://eudragmdp.ema.europa.eu</a> /

This certificate is valid only when presented with all/pages and both Parts 1 and 2 /

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact

the issuing authority.

2025 -08- 1 2

Chief Pharmaceutical Inspecto

Łukasz Pletrzak

12 Senatorska str, 00-082 Warsaw, POLAND phone 22 635 99 51 fax 22 635 99 57 www.gif.gov.pl gif@gif.gov.pl



**Human Medicinal Products** 

1 MA	NUFACTURING OPERATIONS
1.4	Other products or processing activity
	1.4.2 Sterilisation of active substances/excipients/finished product:  1.4.2.6 Electron beam

2025 -08- 1 2

Chief Pharmagentical Inspector

Łukosz Pietrzak

<sup>&</sup>lt;sup>1.</sup> The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 94(1) of Regulation (EU) 2019/6 is also applicable to importers.

